We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Nektar (NKTR) This Earnings Season?
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) is scheduled to report first-quarter 2019 results on May 8 after market close.
While the company surpassed the Zacks Consensus Estimate in two of the last four quarters, it missed the same once and matched it once, with a positive average beat of 3.92%.
Shares of the company have lost 0.6% so far this year against the industry’s increase of 10.1%.
In the last reported quarter, Nektar delivered a positive earnings surprise of 18.57%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Nektar earns revenues from proprietary PEGylation material sales to partners, royalties on sales of partnered drugs like AstraZeneca’s Movantik and Takeda’s Adynovate. Royalty revenues displayed an upward trend in every quarter of 2018 and the momentum is likely to continue in the soon-to-be reported quarter.
The company will focus on its lead candidates, Onzeald (pain management) and NKTR-214 (an immuno-stimulatory CD122-biased agonist) on its first quarter earnings call. Nektar has collaborations with multiple drug companies to develop NKTR-214 in combination with their cancer candidates including Pfizer’s (PFE - Free Report) Bavencio and talazoparib or Xtandi. A phase III study is evaluating NKTR-214 in combination with Bristol-Myers’ (BMY - Free Report) Opdivo for treating first-line advanced melanoma patients. These studies are likely to drive research and development costs higher in the first quarter.
Nektar’s analgesic candidate, NKTR-181, is under FDA review for treating chronic low back pain in patients new to any opioid therapy. A decision is expected in August this year. The company is in the process of creating a commercialization plan for the drug. We expect the company to provide details on commercialization plans following potential approval of NKTR-181. Investor focus will be on updates on late-stage melanoma study on NKTR-214+Opdivo combination therapy and future development plans in other indications.
Earnings Whispers
Our proven model shows that the combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Nektar’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 71 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Nektar’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Image: Bigstock
What's in the Cards for Nektar (NKTR) This Earnings Season?
Nektar Therapeutics (NKTR - Free Report) is scheduled to report first-quarter 2019 results on May 8 after market close.
While the company surpassed the Zacks Consensus Estimate in two of the last four quarters, it missed the same once and matched it once, with a positive average beat of 3.92%.
Shares of the company have lost 0.6% so far this year against the industry’s increase of 10.1%.
In the last reported quarter, Nektar delivered a positive earnings surprise of 18.57%.
Let’s see how things are shaping up for this announcement.
Factors at Play
Nektar earns revenues from proprietary PEGylation material sales to partners, royalties on sales of partnered drugs like AstraZeneca’s Movantik and Takeda’s Adynovate. Royalty revenues displayed an upward trend in every quarter of 2018 and the momentum is likely to continue in the soon-to-be reported quarter.
The company will focus on its lead candidates, Onzeald (pain management) and NKTR-214 (an immuno-stimulatory CD122-biased agonist) on its first quarter earnings call. Nektar has collaborations with multiple drug companies to develop NKTR-214 in combination with their cancer candidates including Pfizer’s (PFE - Free Report) Bavencio and talazoparib or Xtandi. A phase III study is evaluating NKTR-214 in combination with Bristol-Myers’ (BMY - Free Report) Opdivo for treating first-line advanced melanoma patients. These studies are likely to drive research and development costs higher in the first quarter.
Nektar’s analgesic candidate, NKTR-181, is under FDA review for treating chronic low back pain in patients new to any opioid therapy. A decision is expected in August this year. The company is in the process of creating a commercialization plan for the drug. We expect the company to provide details on commercialization plans following potential approval of NKTR-181. Investor focus will be on updates on late-stage melanoma study on NKTR-214+Opdivo combination therapy and future development plans in other indications.
Earnings Whispers
Our proven model shows that the combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Nektar’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 71 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Nektar’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Nektar Therapeutics Price and Consensus
Nektar Therapeutics Price and Consensus | Nektar Therapeutics Quote
A Stock That Warrants a Look
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Horizon Pharma has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8. You can see the complete list of today’s Zacks #1 Rank stocks here.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>